Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 10,763	$ 5,880
Acquired in-process research and development	23,049
General and administrative	3,517	2,815
Total operating expenses	37,329	8,695
Loss from operations	(37,329)	(8,695)
Other expense, net:
Interest expense	(255)	(271)
Interest income	25	26
Other income (expense), net	142	(51)
Total other expense, net	(88)	(296)
Net loss	(37,417)	(8,991)
Other comprehensive (loss) income, net:
Unrealized loss on available-for-sale securities, net	(180)	(3)
Foreign currency translation (loss) gain	(136)	45
Total other comprehensive (loss) income, net	(316)	42
Comprehensive loss	$ (37,733)	$ (8,949)
Net loss per share, basic and diluted	$ (1.17)	$ (0.33)
Weighted-average number of common shares outstanding, basic and diluted	31,865,783	27,325,372